Animal model of longevity and related methods for increasing longevity and inhibiting tumorigenesis
AssigneeAcademia Sinica
InventorsChe-Kun James SHEN, Yu-Chiau SHYU
Life of this patent
Estimating the term…
Abstract
The present invention includes a genetically-modified non-human animal model of longevity and increased health span, which is associated with reduced tumorigenesis and tumor metastasis, as well as related methods for increasing longevity and health span, reducing tumorigenesis and tumor metastasis, and identifying active agents that confer increased longevity or health span, or reduced tumorigenesis or tumor metastasis.
Claims57
A non-human transgenic animal comprising one or more modified Erythroid Kruppel-like factor (EKLF) genes encoding a modified EKLF polypeptide comprising one or more amino acid modifications as compared to a wild-type EKLF polypeptide, wherein the one or more amino acid modifications comprises a modification at an amino acid position that is sumoylated or phosphorylated in the wild-type EKLF polypeptide.
2-4. (canceled)
13-14. (canceled)
A method of treating or preventing a cellular proliferative disorder, or inhibiting or reducing the incidence of tumor occurrence or tumor metastasis, in a subject in need thereof, comprising administering to the subject an effective amount of:
- a) a polypeptide or a nucleic acid encoding the polypeptide, wherein the polypeptide is a modified EKLF polypeptide comprising one or more amino acid modifications that confer decreased sumoylation of the modified EKLF polypeptide as compared to a wild-type EKLF polypeptide, optionally a modified human EKLF polypeptide;
- or
- b) a first active agent that alters one or more activities of an endogenous EKLF polypeptide, optionally an endogenous human EKLF polypeptide.
(canceled)
A method of extending the lifespan or health span of a subject, comprising administering to the subject an effective amount of:
- a) a polypeptide or a nucleic acid encoding the polypeptide, wherein the polypeptide is a modified EKLF polypeptide comprising one or more amino acid modifications that confer reduced sumoylation of the modified EKLF polypeptide as compared to a wild-type EKLF polypeptide, optionally a modified human EKLF polypeptide;
- or
- b) a first active agent that alters one or more activities of an endogenous EKLF polypeptide, optionally an endogenous human EKLF polypeptide.
(canceled)
60-72. (canceled)
Dependencies are inferred from the claim text.